Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Genomic mapping reveals cisplatin disruption of protein phosphorylation signalling genome-wide.

Metallomics : integrated biometal science·2026
Same author

In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling.

Journal of the American Chemical Society·2026
Same author

A Correlative X‑ray Bioimaging Triad for Metals in Biomedical Research.

Chemical & biomedical imaging·2026
Same author

In Situ Lipid Interactions of an Anticancer Metal Complex.

Inorganic chemistry·2026
Same author

Multichiral Half-Sandwich Ru(II) and Os(II) Anticancer Complexes Containing a Glutathione Synthesis Inhibitor.

Organometallics·2025
Same author

Synthetic methods for key precursors of biologically active dimethylsulfoxide ruthenium complexes.

Dalton transactions (Cambridge, England : 2003)·2025

Video Experimental Relacionado

Updated: May 18, 2026

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

Interruptor de triptófano para un complejo anticancerígeno de platino fotoactivado.

Jennifer S Butler1, Julie A Woods, Nicola J Farrer

  • 1Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK.

Journal of the American Chemical Society
|September 21, 2012
PubMed
Resumen

El complejo de platino (IV) trans, trans, trans-[Pt (N3) 2 (OH) 2 (py) 2) (1) muestra una potente toxicidad para las células cancerosas tras la irradiación de luz azul. Este efecto es desactivado por el l-triptófano, que apaga la formación de radicales azidilo.

Más Videos Relacionados

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

Videos de Experimentos Relacionados

Last Updated: May 18, 2026

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

Área de la Ciencia:

  • Química Inorgánica La Química Inorgánica es la química inorgánica.
  • La fotoquímica es la fotoquímica.
  • Terapéutica del cáncer Terapéutica del cáncer.

Sus antecedentes:

  • Los complejos de platino (IV) están siendo investigados para la terapia del cáncer.
  • Los complejos de platino fotoactivados pueden exhibir una potente citotoxicidad.

Objetivo del estudio:

  • Para investigar el mecanismo de fotocitotoxicidad de un complejo específico Pt (IV) complejo.
  • Para explorar el papel del l-triptófano en la modulación de esta fotocitotoxicidad.

Principales métodos:

  • La espectroscopia de resonancia paramagnética de electrones (EPR, por sus siglas en inglés) es una espectroscopia de resonancia paramagnética de electrones.
  • La espectroscopia de resonancia magnética nuclear (RMN) también se conoce como espectroscopia de resonancia magnética nuclear.
  • Técnicas de captura de espinas técnicas de captura de espinas

Principales resultados:

  • El complejo Pt (IV) trans, trans, trans-[Pt (N3) 2 (OH) 2 (py) 2) (1) es citotóxico para las células cancerosas bajo luz visible.
  • El l-triptófano (l-Trp) en dosis bajas (500 microM) inhibe esta fotocitotoxicidad.
  • Los estudios de EPR y RMN indican que el l-Trp apaga la formación de radicales azidil al actuar como un donante de electrones.

Conclusiones:

  • El l-triptófano puede controlar la actividad de los fármacos fotoquimioterapéuticos azido Pt(IV).
  • El mecanismo de doble ataque que involucra a los radicales y los fotoproductos Pt (II) contribuye a la potencia de estos complejos de platino.